Rubín de Célix, CristinaRicart, ElenaMartín Arranz, María DoloresFrancisco, Ruth deGarcía Alonso, Francisco JavierMesonero, FranciscoGomollón, FernandoCastro, Luisa deRamos, LauraPajares, Ramónet al.2026-06-232026-06-232025Rubín De Célix, C., Ricart, E., Martín‐Arranz, M. D., De Francisco, R., García‐Alonso, F. J., Mesonero, F., Gomollón, F., De Castro, L., Ramos, L., García‐López, S., Arias, L., Mañosa, M., Iglesias, E., Calvet, X., Suria Bolufer, C., Casanova, M. J., Pérez‐Calle, J. L., Giordano, A., Sierra‐Ausín, M., … Gisbert, J. P. (2026). Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics, 63(1), 93-108. https://doi.org/10.1111/apt.703120269-2813https://hdl.handle.net/11268/17176Real-world data on dose escalation/de-escalation in inflammatory bowel disease (IBD) are scarce. In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De-escalation is feasible in some patients. Re-escalation is generally effective after relapse.engEnfermedades AutoinmunesEnfermedades Inflamatorias del Intestinojournal article10.1111/apt.70312embargoed accessCiencias médicasInmunologíaFarmacologíaGoal 3: Ensure healthy lives and promote well-being for all at all ages